SecBot SecBot

IBRX

ImmunityBio, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001326110 Biotech & Drug Discovery
$5.98 −0.04 (−0.66%)
Nov 16 4:00 PM ET · prev $6.02
Market cap
$6.5B
Mid cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$14.50
+142% · range $12.00–16.00
1 year
+194.6%
from $2.03 · Nov 17
30 days
−29.0%
from $8.42
52-week range
$1.98–11.55
−48% from high · low Dec 30
Avg volume 20D
13.00M
Nov 9 spike 44.87M
Short interest
126.08M
≈11.9% of shares · +2.5%
Days to cover
10.8
at average volume
Insider net
−$8.0M
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Reddit crowd
60°
Warm · 1 mention this week
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next FDA decision date, Jan 6, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $8.0M.

  • InstitutionsMIXED

    Q3 2026: 31 added (0 new), 21 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +2.5% to 126.08M shares. 10.8 days to cover, ≈11.9% of shares.

  • TrendDOWNTREND

    30% below its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM2,132,042$20.1M
PRINCIPAL FINANCIAL GROUP INCDOUBLED1,737,724$16.4M
MARSHALL WACE, LLPDOUBLED1,450,259$13.7M
Private Advisor Group, LLCDOUBLED884,599$8.4M
Invesco Ltd.ADD558,721$5.3M
Rafferty Asset Management, LLCADD505,914$4.8M
VANGUARD ASSET MANAGEMENT, LtdADD372,654$3.5M
DIMENSIONAL FUND ADVISORS LPDOUBLED309,030$2.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy4Buy5Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +142%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026Jefferies
MAINTAIN
MAINTAINBuy
Oct 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 21, 2026BTIG
REITERATE
REITERATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

Insider ledger

Form 4
$0
bought · 0 insiders
$8.0M
sold · 3 insiders
DateInsiderTypeValue
Oct 5, 2026
Simon Barry J.
Director
Oct 5, 2026
SELL$268.8K
Oct 2, 2026
Cohen Cheryl
Director
Oct 2, 2026
EXERCISE$166.8K
Oct 2, 2026
Cohen Cheryl
Director
Oct 2, 2026
SELL$851.1K
Jul 2, 2026
Cohen Cheryl
Director
Jul 2, 2026
EXERCISE$166.8K
Jul 2, 2026
Cohen Cheryl
Director
Jul 2, 2026
SELL$1.2M
Jul 1, 2026
Selecky Christobel
Director
Jul 1, 2026
EXERCISE$372.0K
Jul 1, 2026
Selecky Christobel
Director
Jul 1, 2026
SELL$1.4M
Jul 1, 2026
Selecky Christobel
Director
Jul 1, 2026
EXERCISE$104.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
IBRX trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
DateMemberType AmountDisclosed
Sep 30, 2026 Lisa McClainRHouse Spouse account · IMMUNITYBIO INC BUY $1K–$15K Oct 12, 2026 +12d
Sep 28, 2026 Lisa McClainRHouse Spouse account · IMMUNITYBIO INC BUY $1K–$15K Oct 12, 2026 +14d

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
126,083,790
shares short
+2.5%
vs prior settlement
10.8
days to cover
≈11.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus revenue estimates of…
8-K · Impact 5/10
Nov 9, 2026 SEC
ImmunityBio announced positive final analysis results from the QUILT-2.005 trial, showing ANKTIVA plus BCG met the…
8-K · Impact 6/10
Nov 5, 2026 Earnings calendar
IBRX Q3 2026 Earnings Scheduled · 2026-11-05
Nov 4, 2026 SEC
Three institutional asset managers added $18.3M in IBRX positions during Q3 2026, led by Principal Financial Group's…
INST-CLUSTER · Impact 3/10
Oct 5, 2026 Insider
Simon Barry J. sold 25,000 shares
Director @ $10.75 ($268.8K)
Oct 2, 2026 Insider
Cohen Cheryl acquired via exercise 55,979 shares
Director @ $2.98 ($166.8K)
Oct 2, 2026 Insider
Cohen Cheryl sold 81,056 shares
Director @ $10.50 ($851.1K)
Sep 30, 2026 Inst.
MORGAN STANLEY · TRIM
2,132,042 shares ($20.1M)
Reddit Mentions per day, 14 days
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
All social signals and their track records

SecBot reports

11 filings · 5 bullish · 0 bearish · 6 neutral
All IBRX filing & press-release reports (11)